论文部分内容阅读
目的:探讨急性脑梗死患者应用葛根素联合阿替普酶治疗临床疗效及其安全性评价。方法:98例急性脑梗死患者根据随机数字表法随机分为对照组和观察组,各49例。对照组给予阿替普酶治疗;观察组在对照组基础上结合葛根素治疗。对比分析两组患者治疗效果及其安全性评价。结果:观察组治疗后总有效率(93.88%)显著高于对照组(79.59%),且有统计学意义(P<0.05);观察组治疗后神经功能缺损评分以及脑梗死体积均明显低于对照组治疗后,且有统计学意义(P<0.05);观察组治疗后IL-6和CRP显著低于同期对照组,且差异具有统计学意义(P<0.05);观察组治疗后全血高切黏度、全血低切黏度、血浆黏度水平明显较对照组治疗后低,且有统计学意义(P<0.05);并且两组均未明显不良反应出现。结论:急性脑梗死患者应用葛根素联合阿替普酶治疗临床疗效显著,无明显不良反应发生,且安全可靠,具有重要研究价值。
Objective: To investigate the clinical efficacy and safety evaluation of puerarin combined with alteplase in patients with acute cerebral infarction. Methods: A total of 98 patients with acute cerebral infarction were randomly divided into control group and observation group according to random number table method, 49 cases in each. The control group was treated with alteplase; the observation group was treated with puerarin on the basis of the control group. Comparative analysis of two groups of patients with treatment and safety evaluation. Results: The total effective rate (93.88%) in the observation group was significantly higher than that in the control group (79.59%) (P <0.05). The scores of neurological deficit and cerebral infarction in the observation group were significantly lower than those in the control group After treatment, the levels of IL-6 and CRP in the observation group were significantly lower than those in the control group (P <0.05), and the difference was statistically significant (P <0.05) High shear viscosity, low shear viscosity of whole blood and plasma viscosity were significantly lower than those of the control group after treatment (P <0.05), and no obvious adverse reactions occurred in both groups. Conclusion: The clinical effect of puerarin combined with alteplase in patients with acute cerebral infarction is significant, no obvious adverse reactions occur, and it is safe and reliable, which has important research value.